Literature DB >> 22354166

DYRK1A in Down syndrome: an oncogene or tumor suppressor?

Yehudit Birger1, Shai Izraeli.   

Abstract

Children with Down syndrome (DS) have a markedly increased risk of developing acute megakaryoblastic leukemia (AMKL) and acute lymphoblastic leukemia compared with that of children without DS. Despite recent breakthroughs, it is not clear which genes on chromosome 21, the chromosome that is trisomic in individuals with DS, cause this predisposition. In this issue of the JCI, Malinge et al. report their loss- and gain-of-function experiments in mouse and human cells that show that increased expression of the kinase encoded by the chromosome 21 gene DYRK1A suppresses the nuclear factor of activated T cells pathway and promotes AMKL. Interestingly, the same protein has been suggested to contribute to the reduced risk of epithelial cancers in adults with DS, leading to the possibility that it could be proleukemic in children and antitumorigenic in adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354166      PMCID: PMC3287238          DOI: 10.1172/JCI62372

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

Review 1.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

2.  Trisomy 21 tilts the balance.

Authors:  Shai Izraeli
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

Review 3.  Infections and immunodeficiency in Down syndrome.

Authors:  G Ram; J Chinen
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

4.  Calcineurin-NFAT signaling critically regulates early lineage specification in mouse embryonic stem cells and embryos.

Authors:  Xiang Li; Lili Zhu; Acong Yang; Jiangwei Lin; Fan Tang; Shibo Jin; Zhe Wei; Jinsong Li; Ying Jin
Journal:  Cell Stem Cell       Date:  2011-01-07       Impact factor: 24.633

Review 5.  Pattern of malignant disorders in individuals with Down's syndrome.

Authors:  H Hasle
Journal:  Lancet Oncol       Date:  2001-07       Impact factor: 41.316

6.  Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.

Authors:  Ashley P Ng; Craig D Hyland; Donald Metcalf; Catherine L Carmichael; Stephen J Loughran; Ladina Di Rago; Benjamin T Kile; Warren S Alexander
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

7.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Authors:  Oliver Tunstall-Pedoe; Anindita Roy; Anastasios Karadimitris; Josu de la Fuente; Nicholas M Fisk; Phillip Bennett; Alice Norton; Paresh Vyas; Irene Roberts
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

8.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.

Authors:  Monika J Stankiewicz; John D Crispino
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

10.  Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.

Authors:  S De Vita; C Canzonetta; C Mulligan; F Delom; J Groet; C Baldo; L Vanes; F Dagna-Bricarelli; A Hoischen; J Veltman; E M C Fisher; V L J Tybulewicz; D Nizetic
Journal:  Oncogene       Date:  2010-08-09       Impact factor: 9.867

View more
  6 in total

1.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

2.  Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.

Authors:  Qiang Liu; Na Liu; Shaolei Zang; Heng Liu; Pin Wang; Chunyan Ji; Xiulian Sun
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 3.  DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.

Authors:  P Fernández-Martínez; C Zahonero; P Sánchez-Gómez
Journal:  Mol Cell Oncol       Date:  2015-01-30

4.  The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.

Authors:  Steven E Guard; Zachary C Poss; Christopher C Ebmeier; Maria Pagratis; Helen Simpson; Dylan J Taatjes; William M Old
Journal:  Sci Rep       Date:  2019-04-25       Impact factor: 4.379

Review 5.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

6.  Low risk of solid tumors in persons with Down syndrome.

Authors:  Henrik Hasle; Jan M Friedman; Jørgen H Olsen; Sonja A Rasmussen
Journal:  Genet Med       Date:  2016-03-31       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.